NOVOGEN ANNOUNCES DEVELOPMENT AND EXPANSION OF U.S. SUBSIDIARY COMPANIES

Novogen Limited (Nasdaq: NVGN -- News; ASX: NRT -- News) today announced the expansion in the U.S. of Glycotex, Inc., its U.S. subsidiary, and the resignation of Dr. Graham Kelly from Novogen's Board of Directors in order for him to focus on the development and expansion of Novogen's U.S. subsidiary companies. Glycotex, Inc.'s business is based on the development of wound-healing glucan compounds, particularly the Company's glucan technology that has been licensed by Novogen to Glycotex. Dr. Kelly developed the intellectual property used by Glycotex.

Yahoo News (http://biz.yahoo.com/prnews/050902/dcf005.html?.v=26)